Baxter International has settled an FDA warning letter it received in January over concerns that it violated good manufacturing practice standards and failed to file post-market reports at its two facilities in Puerto Rico. The company also resolved safety issues related to peritoneal dialysis solutions manufactured at its facility in Ireland.

Full Story:

Related Summaries